The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.
The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.
复制标题
虚拟身心计划对患有神经纤维瘤的国际英语成人的复原力因素的影响：随机临床试验的二次分析。
DOI：
10.1007/s11060-023-04389-1
复制
发表时间：
2023
影响因子：
3.9
通讯作者：
Vranceanu,Ana-Maria
中科院分区：
文献类型：
--
作者：
Presciutti,AlexanderM;Lester,EthanG;Woodworth,EmilyC;Greenberg,Jonathan;Bakhshaie,Jafar;Hooker,JuliaE;McDermott,KatherineA;Vranceanu,Ana-Maria
目的测试放松反应弹性计划 - 神经纤维瘤病 (3RP-NF)（一项针对 NF 患者的身心弹性计划）对从基线到治疗后以及 6 个月和 12 个月随访的弹性因素的影响。方法这是对 3RP-NF 和健康教育控制 (HEP-NF) 的全动力随机临床试验 (RCT) 的二次分析。我们招募了患有 NF1、NF2 或神经鞘瘤病的成年人，他们报告说有压力或难以应对 NF 症状。两种情况均每周接受 8 次 90 分钟的小组治疗； 3RP-NF 专注于培养复原力技能。我们通过当前状态测量-A（适应性应对）、认知和情感正念量表-修订版（正念）、感恩问卷-6（感恩）、生活取向测试乐观量表（乐观）和医疗结果研究社会支持调查（感知社会支持）在基线、干预后以及6个月和12个月的随访中测量复原力因素。我们使用具有完全非结构化协方差的线性混合模型，在多达四次重复测量（基线、治疗后以及 6 个月和 12 个月的随访）中研究治疗对弹性因素的影响。结果我们招募了 228 名个体（Mage=42.7，SD= 14.6；74.5% 女性；87.7% 白人；72.8% NF1，14.0% NF2， 13.2% 神经鞘瘤病）。在组内，3RP-NF 和 HEP-NF 在各个时间点的所有结果上均显示出统计上显着的改善。与 HEP-NF 相比，从基线到干预后以及基线到 6 个月，3RP-NF 在适应性应对方面表现出显着更大的改善（Mdifference = 0.29; 95% CI 0.13–0.46;p< 0.001;Mdifference= 0.25; 95% CI 0.07–0.33;p= 0.005）；其余弹性因素之间没有其他组间差异。结论 3RP-NF 在持续提高 NF 患者的应对能力方面表现出了希望。试验注册信息 ClinicalTrials.gov 标识符：NCT03406208。注册于 2017 年 12 月 6 日提交，第一位患者于 2017 年 10 月入组。
PurposeTo test the effects of the Relaxation Response Resiliency Program - Neurofibromatosis (3RP-NF), a mind-body resilience program for people with NF, on resilience factors from baseline to post-treatment and 6- and 12-month follow-up.MethodsThis is a secondary analysis of a fully powered randomized clinical trial (RCT) of 3RP-NF and health education control (HEP-NF). We recruited adults with NF1, NF2, or schwannomatosis who reported stress or difficulty coping with NF symptoms. Both conditions received 8 weekly 90-minute group sessions; 3RP-NF focused on building resilience skills. We measured resilience factors via the Measure of Current Status-A (adaptive coping), Cognitive and Affective Mindfulness Scale-Revised (mindfulness), Gratitude Questionnaire-6 (gratitude), Life Orientation Test Optimism Scale (optimism), and Medical Outcomes Study Social Support Survey (perceived social support) at baseline, post-intervention, and 6- and 12-month follow-up. We used linear mixed models with completely unstructured covariance across up to four repeated measurements (baseline, post-treatment, and 6- and 12-month follow-up) to investigate treatment effects on resilience factors.ResultsWe enrolled 228 individuals (Mage=42.7,SD= 14.6; 74.5% female; 87.7% White; 72.8% NF1, 14.0% NF2, 13.2% schwannomatosis). Within groups, both 3RP-NF and HEP-NF showed statistically significant improvements in all outcomes across timepoints. 3RP-NF showed significantly greater improvement in adaptive coping compared to HEP-NF from baseline to post-intervention and baseline to 6 months (Mdifference= 0.29; 95% CI 0.13–0.46;p< 0.001;Mdifference= 0.25; 95% CI 0.07–0.33;p= 0.005); there were no other between-group differences amongst the remaining resilience factors.Conclusion3RP-NF showed promise in sustainably improving coping abilities amongst people with NF.Trial registration InformationClinicalTrials.gov Identifier: NCT03406208. Registration submitted December 6, 2017, first patient enrolled October 2017.